Quantcast

Latest Natalizumab Stories

2014-09-22 08:26:16

TOORAK, Australia, Sept. 22, 2014 /PRNewswire/ -- Antisense Therapeutics (the "Company" or "ANP") is pleased to report the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology. The article titled "CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS", is currently available online and will be included in the print edition Volume 83, November 11, 2014. The article highlights the...

2014-09-09 04:21:06

~Convening World's Leading Researchers in MS with a Program Covering all Aspects of Research Including Cause and Pathology, Genetics and Environmental Impact, Emerging Treatment Study Findings and Nervous System Repair BOSTON, Sept. 9, 2014 /PRNewswire/ -- On September 10-13 at the Hynes Convention Center in Boston, MA, ACTRIMS-ECTRIMS will host their joint triennial international meeting - MSBoston 2014, with over 8,000 participant from leading organizations in Europe, North America and...

2014-08-07 12:28:48

Biogen Idec's Tecfidera is Forecast to Overtake Teva's Copaxone Franchise as the U.S. Market Leader by 2015, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, coupled with the expected U.S. approval of Genzyme/Sanofi/Bayer HealthCare's...

2014-07-22 12:27:43

Genzyme/Sanofi's Lemtrada and Genentech/Roche's Ocrelizumab Will Likely Be Reserved for Patients with Aggressive/Severe MS, According to Findings from Decision Resources Group BURLINGTON, Mass., July 22, 2014 /PRNewswire/ -- Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing and/or gastrointestinal events while on the therapy. However, few...

2014-06-26 12:29:42

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Multiple Sclerosis -- KOL Insight and Consensus Outlook Moduleshttp://www.reportbuyer.com/pharma_healthcare/diseases/multiple_sclerosis_kol_insight_consensus_outlook_modules.html IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen's Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market...

2014-03-24 12:24:47

Surveyed U.S. Payers Also Seek Improvements from New Agents in Effect on Disability, According to Findings from Decision Resources Group BURLINGTON, Mass., March 24, 2014 /PRNewswire/ -- Decision Resources Group finds that new disease-modifying therapies (DMTs) with improved efficacy in slowing disability progression present the greatest opportunity for drug developers in the treatment of relapsing-remitting multiple sclerosis (RR-MS). This finding is based on the relatively high level of...

2014-02-20 12:25:06

CHERRY HILL, N.J., Feb. 20, 2014 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is pleased to offer the latest MS Research Update, available as both a printed and online publication. This vital resource provides a comprehensive overview of research findings on the ten FDA-approved disease-modifying therapies for relapsing forms of multiple sclerosis (MS), as well as the latest study results on many experimental treatments currently under investigation. Directions...

2013-11-30 23:03:24

MarketReportsOnline.com offers “Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)” research that analyzes the global market sizing and growth of multiple sclerosis in terms of revenue, number of patients and sales of effective drugs. Dallas, Texas (PRWEB) November 30, 2013 The report titled "Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)" provide an insight into the market dynamics and various trends and opportunities associated...

2013-11-21 23:20:17

Reportbuyer.com just published a new market research report: Multiple Sclerosis: KOL Insight. London (PRWEB) November 21, 2013 The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen’s Tecfidera (dimethyl fumarate) has revolutionised multiple sclerosis treatment in the US, eroding significant market share from older therapies. However, patent concerns has stalled Tecfidera’s launch in Europe. Genzyme have taken advantage of this delay with...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related